Jeffrey M Harris, Romeo Maciuca, Mary S Bradley, Christopher R Cabanski, Heleen Scheerens, Jeremy Lim, Fang Cai, Mona Kishnani, X Charlene Liao, Divya Samineni, Rui Zhu, Colette Cochran, Weily Soong, Joseph D Diaz, Patrick Perin, Miguel Tsukayama, Dimo Dimov, Ioana Agache and Steven G Kelsen. “A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma.” Respir Res 2016 18;17:29.
Sarbjit S Saini, Carsten Bindslev-Jensen, Marcus Maurer, Jean-Jacques Grob, Emel Bülbül Baskan, Mary S Bradley, Janice Canvin, Abdelkader Rahmaoui, Panayiotis Georgiou, Oral Alpan, Sheldon Spector and Karin Rosén. “Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.” J Invest Dermatol 2015 Jan 21;135(1):67-75.
Aidan Long, Abdelkader Rahmaoui, Kenneth J Rothman, Eva Guinan, Mark Eisner, Mary S Bradley, Carlos Iribarren, Hubert Chen, Gillis Carrigan, Karin Rosén and Stanley J Szefler. “Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab.” J Allergy Clin Immunol 2014 Sep 27;134(3):560- 567.
Mark D Eisner, James L Zazzali, Mary K Miller, Mary S Bradley and Michael Schatz. “Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study.” J Asthma 2012 Aug;49(6):642-8
Aidan A. Long, James E. Fish, Abdelkader Rahmaoui, Mary K. Miller, Mary S. Bradley, Hassan N. Taki, Anthony N. Demeo, Stephen A. Tilles, and Stanley J. Szefler. “Baseline characteristics of patients enrolled in EXCELS: a cohort study.” Ann Allergy Asthma Immunol 2009 Sep;103(3):212-9
Publications